The value of faecal calprotectin (CPT) in monitoring the response to treatment of patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN81965907

Enrollment

Registered

2003-09-12

Start date

2003-01-17

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease Digestive System Crohn's disease [regional enteritis]

Interventions

Patients with active inflammatory bowel disease will be treated for 2 weeks according to the advice of their clinicians with either oral prednisolone 40 mg daily (ulcerative colitis or Crohn's) or ent

clinical relapse rates in those whose CPTs after the initial 2 weeks treatment were greater, or less, than 250 µg/g will be compared. Updated 28/04/2015: the trial was stopped due to participant recr

Eligibility

Inclusion criteria

Inclusion criteria: 80 patients

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026